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Abstract 
Background: Monoallelic expression (MAE) is a frequent genomic phenomenon in normal tissues, however its role 
in cancer is yet to be fully understood. MAE is defined as the expression of a gene that is restricted to one allele in 
the presence of a diploid heterozygous genome. Constitutive MAE occurs for imprinted genes, odorant receptors 
and random X inactivation. Several studies in normal tissues have showed MAE in approximately 5–20% of the cases. 
However, little information exists on the MAE rate in cancer. In this study we assessed the presence and rate of MAE in 
melanoma. The genetic basis of melanoma has been studied in depth over the past decades, leading to the identifi‑
cation of mutations/genetic alterations responsible for melanoma development.
Methods: To examine the role of MAE in melanoma we used 15 melanoma cell lines and compared their RNA‑seq 
data with genotyping data obtained by the parental TIL (tumor infiltrating lymphocytes). Genotyping was performed 
using the Illumina HumanOmni1 beadchip. The RNA‑seq library preparation and sequencing was performed using 
the Illumina TruSeq Stranded Total RNA Human Kit and subsequently sequenced using a HiSeq 2500 according to 
manufacturer’s guidelines. By comparing genotyping data with RNA‑seq data, we identified SNPs in which DNA geno‑
types were heterozygous and corresponding RNA genotypes were homozygous. All homozygous DNA genotypes 
were removed prior to the analysis. To confirm the validity to detect MAE, we examined heterozygous DNA genotypes 
from X chromosome of female samples as well as for imprinted and olfactory receptor genes and confirmed MAE.
Results: MAE was detected in all 15 cell lines although to a different rate. When looking at the B‑allele frequencies 
we found a preferential pattern of complete monoallelic expression rather then differential monoallelic expression 
across the 15 melanoma cell lines. As some samples showed high differences in the homozygous and heterozygous 
call rate, we looked at the single chromosomes and showed that MAE may be explained by underlying large copy 
number imbalances in some instances. Interestingly these regions included genes known to play a role in melanoma 
initiation and progression. Nevertheless, some chromosome regions showed MAE without CN imbalances suggesting 
that additional mechanisms (including epigenetic silencing) may explain MAE in melanoma.
Conclusion: The biological implications of MAE are yet to be realized. Nevertheless, our findings suggest that MAE is 
a common phenomenon in melanoma cell lines. Further analyses are currently being undertaken to evaluate whether 
MAE is gene/pathway specific and to understand whether MAE can be employed by cancers to achieve a more 
aggressive phenotype.
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Background
Monoallelic gene expression (MAE) is defined as the 
expression of a gene from a single allele against the 
background of a diploid heterozygous genome. In diploid 
mammalian cells, expression of each gene is generally 
achieved through equal expression of the two homolo-
gous alleles. However, there are several cases in which 
only one allele is expressed. There are well character-
ized examples where MAE has been observed previously, 
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of one allele according to the parental origin), random 
inactivation of one X chromosome (lyonization) in 
females and has also been reported in large gene families 
in the nervous and immune systems, such as the olfactory 
receptor gene family, prothocaderins and immunoglobu-
lins, to generate cellular identity and diversity [1–5]. Ran-
dom monoallelic gene expression has been also observed 
in genes that are scattered throughout the genome and 
do not fall into any clusters [6–8]. Recently, several stud-
ies have evaluated the role of random MAE and differen-
tial allele-specific expression (DAE) in normal tissues as 
well as in some diseases including cancer [6, 9–14]. The 
rate of random MAE and DAE has been reported to be 
different between individuals. In cancer MAE/DAEs role 
is yet to be fully understood.
In this study we have evaluated whether MAE/DAE 
occurs in melanoma cell lines. Metastatic cutaneous 
melanoma is aggressive form of skin cancer, its inci-
dence is increasing; melanoma has a complex etiology 
which has posed a challenge in targeted therapies [15]. 
The molecular component of melanoma progression 
is well understood with the mitogen-activated protein 
kinases (MAPK/ERK) pathway being the most commonly 
mutated. Activation of MAPK/ERK signaling is achieved 
through gain of function mutations in BRAF or NRAS 
or through autocrine growth factor stimulation [16–18]. 
Constitutive activating mutations are found in the kinase 
domain of BRAF with a frequency of 50–70%, the most 
common mutation T1799A causes the V600E amino 
acid substitution and a greater than 400-fold increase in 
basal activity as compared to wild type BRAF [18]. NRAS 
mutations that activate the MAPK/ERK pathway occur 
in 15–20% of melanomas and result in the reduction of 
intrinsic GTPase activity and the constitutive activation 
of NRAS. Both genetic and functional studies indicate 
that BRAF and NRAS act linearly in the same pathway, 
this is confirmed by the almost mutually exclusiveness 
of mutations in these genes and the consequent down-
stream activation. Other genetic alterations implicated 
in the progression of melanoma include deletions of the 
CDKN2A locus, genes encoding the Notch proteins or 
involved in the Notch signaling pathway, Wnt signaling 
pathway, PI3 K/Akt signaling pathway, Endothelins (vas-
oactive family of peptides), Micropthalmia-associated 
transcription factor and Sox proteins.
MAE as a consequence of genomic losses, gains, loss 
of heterozygosity (LOH) and epigenetic factors is docu-
mented as a causative mechanism of disease [19]. How-
ever, the MAE role in cancer has yet to be fully addressed.
In this study we genotyped DNA and performed RNA 
sequencing in order to identify SNPs in which DNA gen-
otypes were heterozygous and corresponding RNA geno-
types were homozygous. We used the Illumina platform 
for SNP genotyping arrays as well as for RNA sequenc-
ing. We found that MAE does occur in melanoma and 
involves several genes related to cancer.
Materials and methods
Specimens
Fifteen melanoma cell lines and tumor infiltrating lym-
phocytes were derived from metastatic melanoma lesions 
from patients treated at the Surgery Branch, National 
Cancer Institute (NCI), Bethesda, MD, USA kindly 
donated by Dr. Steven A. Rosenberg. Identity of mela-
noma cell lines and parental tissues was carried out by 
HLA phenotyping as previously described [20].
Ethics, consent and permissions
All patients signed an informed consent approved by 
the Institutional Review Board of the National Cancer 
Institute.
Microarray analysis
Genomic DNA was isolated from tumour infiltrating 
lymphocyte samples using the QIAmp DNA Mini Kit 
(Qiagen, Germantown, MD) according to the manufac-
turers guidelines. DNA quality and quantity was assessed 
using Nanodrop (ThermoScientific, Pittsburgh, PA). 
Samples were genotyped using Illumina Human 1  M 
Beadchip. Samples have been processed according to the 
Illumina procedure for the Infinium II assay. Data was 
extracted by the Illumina BeadArray reader. Samples and 
markers with call rate below 95% were excluded from 
analysis and a GenCall cutoff score of 0.15 was used for 
all Infinium II products. The SNP data was filtered by 
GenTrain score with a hard cut off of < 0.5 being excluded 
from further analysis. Heterozygous SNP calls for each 
sample were exported and subsequently compared to the 
genotype derived from the RNA-seq data.
RNA sequencing
Total RNA was isolated from the cell lines using miRNe-
asy minikit (Qiagen) according to the manufacturer’s 
protocol. RNA quality and quantity was estimated using 
Nanodrop (Thermo Scientific) and Agilent 2100 Bio-
analyzer (Agilent Technologies, Santa Clara, CA, USA). 
Enrichment in mRNA molecules was obtained using 
oligo (dT) magnetic beads  (Ambion® Poly (A)Pur-
ist™ MAG Kit). Subsequently, mRNA was fragmented 
into shorter fragments (approximately 200  bp), cDNA 
was synthesized by random hexamer primers (Illumina 
TruSeq Stranded mRNA Library Prep Kit). The double-
stranded cDNA was purified by QiaQuick PCR extrac-
tion kit (Qiagen) and went through an end repair process 
with the addition of a single ‘A’ base, and then ligation 
of the adapters. These products were then purified by 
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agarose gel electrophoresis and enriched with PCR to 
create the final cDNA library. The library products were 
sequenced and 300 bp sequences were generated via the 
GAIIx Illumina sequencing platform. Raw reads were 
imported on a commercial data analysis platform CLC 
Genomics Workbench (CLC bio, MA, USA). Quality 
control checks on raw sequence data from each sample 
were performed using the QC analysis application tool. 
Adapter trimming was done to remove ligated adapter 
from 3′ end of the sequenced reads with only one mis-
match allowed. After reads have been processed to meet 
a quality standard, they were aligned to the Human refer-
ence genome UCSC-Hg19, using the ultra high-through-
put short aligner provided by CLC bio software. Next, 
after a Transcript Discovery analysis we obtained a tran-
script annotation file with an estimation of the relative 
abundances of each transcript by counting the number of 
reads that mapped to the genomic location of that tran-
script. Transcription level assessment has been obtained 
by the number of fragments per kilobase of transcript per 
million fragments mapped (RPKM).
Array comparative genomic hybridization
DNA from cell lines was isolated using QIAamp DNA 
mini kit (Qiagen). For the healthy diploid reference, 
1.5  μg genomic DNA was isolated from the PBMCs of 
a healthy female donor using  QIAamp® DNA Mini Kit 
(Qiagen). DNA was fragmented, labeled, purified, and 
hybridized to Agilent 2 × 105  K arrays according to the 
Agilent Oligonucleotide Array-Based CGH for Genomic 
DNA Analysis (version 6.2.1). Washing and scanning 
in Agilent BioScanner B took place immediately after 
hybridization. Data was extracted using Agilent’s Feature 
Extraction Software. The featured extracted data from 
the 15 cell lines was analysed using Agilent CytoGenom-
ics Software. Aberrations were called using the ADM-2 
default algorithm using a threshold of 6.0.
Data analysis
Genotyping data of the 15 cell lines has been filtered to 
include only SNPs with heterozygous calls. Genotypes for 
the corresponding positions in the RNA-seq data were 
calculated, the genotypes were assigned using GATK. In 
order to increase the number of informative SNPs (with 
heterozygous calls at the DNA level) we have performed 
imputation analysis using IMPUTE v2 [21]. The follow-
ing data analysis steps were automated using custom Perl 
scripts. We have ascertained the B-allele frequency in 
the RNA sequencing data where the SNP was heterozy-
gous in the microarray analysis and mapped to the RNA 
sequencing data with > 5 reads. SNPs were mapped to 
UCSC gene CDS. SNPs outside CDS were excluded as 
potentially not representative of the gene. The number 
of SNPs monoallelically expressed was calculated, across 
each sample and each gene using user defined threshold 
for number of samples and the number of SNPs per gene. 
Functional network analysis was performed using the 
Ingenuity Pathway Analysis (IPA) tools 3.0 which trans-
forms large data sets into a group of relevant networks 
containing direct and indirect relationships between 
genes based on known interactions in the literature 
(http://www.ingen uity.com, Ingenuity System Inc., Red-
wood City, CA, USA).
Results
Genome wide rate of MAE in metastatic melanoma
MAE frequency was calculated as the sum of the 
homozygous SNPs at the RNAseq data divided by the 
sum of all informative SNPs (with heterozygous calls at 
the DNA level and mapped at the RNA-seq data). To 
increase the number of informative SNPs we performed 
imputation analysis (Table  1). MAE frequency ranged 
between 0.17 and 0.77 across the 15 pairs of melanoma 
cell lines—TILs (non-imputed average 0.58 ± 0.23, 
imputed average 0.60 ± 0.21), suggesting that MAE 
occurs in metastatic melanoma with an overall high fre-
quency as compared to the MAE frequency reported in 
normal conditions. In order to investigate whether DAE 
does also occur in melanoma, B-allele frequency of the 
SNPs with heterozygous calls at the DNA level was calcu-
lated for the RNA-seq data and plotted against the occur-
rence count (Fig. 1a). B-allele frequency showed a normal 
distribution when ranging between 0.1 and 0.9. However, 
the occurrence count peaked when B-allele frequency 
Table 1 MAE frequency across the 15 cell lines
Cell line Mutational status MAE frequency MAE 
frequency 
imputed
Mel2805 WT 0.26 0.36
Mel1866 NRAS mut 0.72 0.77
Mel2075 NRAS mut 0.77 0.80
Mel2155 NRAS mut 0.73 0.76
Mel2427 NRAS mut 0.56 0.65
Mel2744 NRAS mut 0.39 0.47
Mel3107 NRAS mut 0.35 0.43
Mel2035 BRAF mut 0.75 0.79
Mel2224 BRAF mut 0.76 0.80
Mel2448 BRAF mut 0.74 0.77
Mel2458 BRAF mut 0.18 0.28
Mel2492 BRAF mut 0.68 0.73
Mel2523 BRAF mut 0.29 0.36
Mel3025 BRAF mut 0.74 0.79
Mel3104 BRAF mut 0.17 0.28
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was 0 or 1, suggesting that monoallelic expression in mel-
anoma seems to be complete rather than skewed.
The MAE frequency for imputed data was overall 
similar to the one calculated for the non-imputed data, 
suggesting that the MAE frequency was not biased by 
the imputation analysis. For all the further analyses we 
used the imputed data as this was considered to be more 
informative.
MAE rate does not differ between BRAF and NRAS mutated 
melanoma samples
With the hypothesis that activation of oncogenic path-
ways might modify the overall transcriptional program 
and therefore, the MAE pattern, we assessed whether 
MAE rate was different between NRAS and BRAF 
mutated cell lines. The MAE rate in NRAS mutated cell 
lines was slightly higher than in the BRAF mutated cell 
lines (NRAS average 0.58, standard deviation 0.18, BRAF 
average 0.27, standard deviation 0.18, Fig.  1b), however 
the difference was not significant (t test p = 0.7). The only 
BRAF and NRAS wild type cell line available in this study 
had a MAE rate of 0.26.
Is MAE chromosome specific?
To assess whether MAE was functionally enriched in 
given chromosomes, we have calculated the MAE fre-
quency by cell lines and according chromosomes across 
all the 15 pairs of samples (Table  2, Additional file  1: 
Figure S1).
Interestingly, when we looked at the MAE frequency 
by chromosome across cell lines, we found chromo-
some 9 to be frequently MAE expressed (11 out 15 cell 
lines, Fisher’s test of chromosome 9 vs all, two-tailed 
p = 0.0001).
Is MAE explained by CN?
As some of the samples analyzed showed high differ-
ences between homozygous and heterozygous calls, 
we sought to determine whether loci under MAE were 
located within regions of copy number changes (see 
Additional file  2: Figure S2). We found that not in all 
instances MAE was explainable by CN, suggesting that 
additional mechanisms may influence MAE occurrence 
in melanoma. As an example in Mel2744, MAE was 
completely explained by CN in chromosomes 1, 9, 17 
and 18 (Additional file 1: Figure S1).
Detection of novel targets by MAE
With the assumption that MAE plays a role in mela-
noma development, we sought to determine whether 
the genes under MAE were related to tumor pathways. 
We have first filtered genes with at least two informa-
tive SNPs showing MAE, and then selected the genes 
that were shared by at least 8 cell lines, this allowed us 
to identify 515 genes. When imported on IPA, these 
genes pointed ‘Cancer’ as the top disease with a p-value 
range of 2.36E−03–9.06E−24 and 431 molecules repre-
sented in this category, suggesting that the genes under 
MAE in melanoma are indeed related to cancer.
Discussion
MAE has been described as a common phenomenon in 
imprinted genes, immune receptors and olfactory recep-
tors and has also been reported to occur in normal tis-
sues [3, 6]. Nevertheless, the extent of MAE in melanoma 
has never been reported to the best of our knowledge. 
This study addresses the question whether MAE exists in 
melanoma, if so what is its rate, and whether it is higher 
in tumor related genes. We have found that the extent of 
MAE ranges between 17 and 77% (28% to 80%, imputed 
data), suggesting that MAE is a relatively common phe-








































Fig. 1 B‑allele frequency across the fifteen pairs of melanoma cell lines—TILs (a). MAE frequency in NRAS mutated and BRAF mutated samples (b)
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in BRAF mutated versus NRAS mutated melanoma sam-
ples we did not find any statistically significant difference, 
suggesting that MAE rate may not be related to the muta-
tion status of BRAF or NRAS gene. However, this study 
has the limitation of sample size, we cannot exclude that 
by increasing the number of samples the difference in 
MAE rate may become significant.
The molecular mechanisms underlying MAE are still 
to be understood. To determine whether the MAE we 
observed at the genome-wide level was potentially due 
to allele-specific copy number changes, we examined 
whether the homozygous calls at the RNA level were 
located within regions of copy number changes. We used 
aCGH data to assess copy number across the autosomes 
of the 15 TIL samples. We found that in several instances 
MAE was in fact explained by large copy numbers. 
However, the presence of large copy number changes 
explained MAE only partially. Several potential mecha-
nisms that may explain MAE are being studied, including 
DNA methylation, histone modification, DNA replica-
tion timing and nuclear organization [22]. DNA methyla-
tion is perhaps one of the best understood mechanisms 
by which transcriptional states can be inherited through 
the cell cycle and through development [23, 24], and it 
has been demonstrated to be important for other clas-
sic examples of monoallelic expression such us genomic 
imprinting [25]. Monoallelically expressed genes have 
been reported to show increased levels of DNA meth-
ylation when compared with biallelic expressed genes. 
Nevertheless, the comparison of methylation levels 
between monoallelic and biallelic clones revealed that 
some genes showed increased levels of DNA methylation 
in monoallelic clones but others showed no correlation 
between monoallelic expression and DNA methylation 
[8, 26]. We are evaluating whether the pattern of monoal-
lelic expressed genes in our melanoma cell lines may be 
explained by differential methylation at least in part.
Further studies are warranted to confirm our results 
as well as to investigate whether MAE may have clini-
cal implications. Walker and colleagues showed that 
MAE can be used to predict survival in mutated brain 
tumors [9]. Whether this is true for melanoma is still to 
be addressed.
To assess whether MAE is the result of the genomic 
instability of tumors or whether it may play a role for 
tumor development we performed functional interpre-
tation analysis. We selected 515 genes with at least two 
informative SNPs under MAE which were shared by at 
least 8 melanoma cell lines. Functional interpretation 
analysis revealed ‘Cancer’ as the top disease suggesting 
that indeed the genes under monoallelic expression are 
related to cancer.
Conclusion
In conclusion we have shown that melanoma is charac-
terized by a high rate of MAE and genes under MAE are 
related to cancer. Additional studies are required to vali-
date our findings and to assess whether MAE may have 
clinical implications.
Additional files
Additional file 1: Figure S1. MAE rate displayed according to cell lines 
and chromosomes.
Additional file 2: Figure S2. aCGH data from the 15 cell lines analysed 
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ADM‑2 default algorithm using a threshold of 6.0. Losses are represented 
by blocks of red and gains by blocks of blue. Chromosomes are displayed 
left to right 1‑22, X and Y for each cell line.
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